Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
Earnings Data
Report Date
May 06, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.76Last Year’s EPS
0.62Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum driven by CABOMETYX (17% full-year U.S. growth; Q4 growth) and a materially positive regulatory milestone with ZANZA NDA acceptance and a 20% ITT OS benefit in STELLAR-303, supported by a broad pivotal development program and healthy cash plus aggressive share repurchases. Offsetting risks include rising operating expenses, anticipated higher gross-to-net deductions (31–32% guidance for 2026) driven by channel variability and a 2% Medicare Part D discount, and remaining regulatory/clinical uncertainty tied to immature NLM OS data and the outcomes of several pivotal trials. Overall, the positive commercial and pipeline developments and strong balance sheet outweigh the near-term financial and regulatory risks.Company Guidance
Strong Full-Year and Quarterly Revenue Growth for CABOMETYX
Full year 2025 U.S. cabozantinib franchise net product revenues grew ~17% to approximately $2.12 billion versus 2024. Q4 2025 U.S. cabozantinib franchise net product revenues grew ~6% year-over-year to $547 million (CABOMETYX net product revenues $544.7 million). Global cabozantinib franchise net product revenues were approximately $754 million in Q4 and $2.89 billion for full year 2025.
CABOMETYX Leadership in Key Indications
CABOMETYX remained the number-one prescribed TKI in renal cell carcinoma (RCC), the leading TKI+IO combination in first-line RCC, and the number-one oral agent in the second-line-plus neuroendocrine tumor (NET) segment. CABO U.S. net revenues for NET exceeded $100 million in 2025.
ZANZA NDA Acceptance and Positive STELLAR-303 Result (ITT)
FDA accepted the NDA for zanzalintinib (ZANZA) in combination with atezolizumab for third-line-plus colorectal cancer based on STELLAR-303. The trial met one of two dual primary endpoints, showing a 20% reduction in the risk of death in the ITT population at final analysis. PDUFA target action date set for December; top-line non-liver-metastases (NLM) OS readout expected midyear.
Expanding ZANZA Development Program with Multiple Pivotal Trials
ZANZA program includes seven ongoing/planned pivotal trials (e.g., STELLAR-316 MRD adjuvant CRC, STELLAR-311 NET vs everolimus, STELLAR-304 non-clear cell RCC vs sunitinib, STELLAR-201 meningioma). Collaboration interest (e.g., Merck LightSPARK 33 and other combos) could broaden development and commercial potential.
Strong Balance Sheet and Active Capital Return
Cash and marketable securities of approximately $1.66 billion at year-end 2025. Repurchased ~$954 million of common stock in FY2025 (retiring ~24 million shares at an average price of $39.61); ~$590 million remaining on the $750 million repurchase authorization.
Early-Stage Pipeline Progress
Four early clinical molecules (XL-309, XP-010, XB-628, XB-371) are in clinical development and progressing. Additional small molecule and ADC programs are advancing, supporting the company’s franchise-building strategy beyond CABO and ZANZA.
EXEL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EXEL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 10, 2026 | $42.98 | $42.94 | -0.09% |
Nov 04, 2025 | $37.90 | $40.37 | +6.52% |
Jul 28, 2025 | $44.39 | $36.94 | -16.78% |
May 13, 2025 | $36.95 | $44.65 | +20.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Exelixis (EXEL) report earnings?
Exelixis (EXEL) is schdueled to report earning on May 06, 2026, After Close (Confirmed).
What is Exelixis (EXEL) earnings time?
Exelixis (EXEL) earnings time is at May 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EXEL EPS forecast?
EXEL EPS forecast for the fiscal quarter 2026 (Q1) is 0.76.